ARDELYX, INC.·4

Sep 16, 6:14 PM ET

Rosenbaum David P. 4

4 · ARDELYX, INC. · Filed Sep 16, 2024

Insider Transaction Report

Form 4
Period: 2024-09-13
Rosenbaum David P.
SVP, Drug Development
Transactions
  • Sale

    Common Stock

    2024-09-13$6.26/sh5,312$33,254153,616 total(indirect: By Spouse)
Holdings
  • Common Stock

    351,510
  • Common Stock

    (indirect: By Trust)
    77,592
Footnotes (4)
  • [F1]Transaction was executed in multiple trades in prices ranging from $6.2601 to $6.265, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote
  • [F2]Reflects the adjusted total which includes the purchase of 2,676 shares under the Ardelyx Employee Stock Purchase Plan in August 2024.
  • [F3]The shares are directly held by the Reporting Person's wife.
  • [F4]The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.

Documents

1 file
  • 4
    wk-form4_1726524865.xmlPrimary

    FORM 4